AbbVie Inc (ABBV)vsAgnico Eagle Mines Limited (AEM)
ABBV
AbbVie Inc
$207.18
+0.96%
HEALTHCARE · Cap: $362.83B
AEM
Agnico Eagle Mines Limited
$192.07
+4.68%
BASIC MATERIALS · Cap: $89.62B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 414% more annual revenue ($61.16B vs $11.91B). AEM leads profitability with a 37.5% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.49. AEM earns a higher WallStSmart Score of 73/100 (B).
ABBV
Buy63
out of 100
Grade: C+
AEM
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1190.8%
Fair Value
$16.05
Current Price
$207.18
$191.13 premium
Margin of Safety
+47.7%
Fair Value
$415.12
Current Price
$192.07
$223.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Keeps 38 of every $100 in revenue as profit
Strong operational efficiency at 64.7%
Revenue surging 60.3% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Generating 1.3B in free cash flow
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
2.0% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : AEM
The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 37.5% and operating margin at 64.7%. Revenue growth of 60.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.
Bear Case : AEM
The primary concerns for AEM are EPS Growth, PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while AEM is a growth play — different risk/reward profiles.
AEM carries more volatility with a beta of 0.61 — expect wider price swings.
AEM is growing revenue faster at 60.3% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
AEM scores higher overall (73/100 vs 63/100), backed by strong 37.5% margins and 60.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Agnico Eagle Mines Limited
BASIC MATERIALS · GOLD · USA
Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?